SCHEMBL1021644

SCHEMBL1021644

CCC(C)NC(=O)c1cccc(CN2CCN(C(=O)O)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
HTT P42858 1/20 0.56
HDAC1 Q13547 1/20 0.51
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
HIF1A Q16665 1/20 0.50
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 1/20 0.48
ALOX15 P16050 1/20 0.46
CYP2C19 P33261 1/20 0.46
GAA P10253 1/20 0.46
AGTR2 P50052 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020064 0.85 PKM (0.47) PKMHTTHDAC1ALDH1A1KDM4E
SCHEMBL1020065 0.85 PKM (0.47) PKMHTTHDAC1ALDH1A1KDM4E
SCHEMBL1020290 0.85 CHRM3 (0.61) CHRM3
SCHEMBL1020291 0.85 CHRM3 (0.61) CHRM3
SCHEMBL4838001 0.81 CYP2D6 (0.73) CYP2D6CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL1022150 0.81 MEN1 (0.47) PKMHTTALDH1A1KDM4EMEN1
SCHEMBL1022152 0.81 MEN1 (0.47) PKMHTTALDH1A1KDM4EMEN1
SCHEMBL7038584 0.79 SMN1; SMN2 (0.59) HTTCYP2D6CYP2C9HIF1AALDH1A1
SCHEMBL6630922 0.78 MEN1 (0.61) CYP2D6CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL1020776 0.76 CYP2D6 (0.52) PKMHDAC1CYP2D6CYP2C9HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
EP-2190827-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. Organon (NL) 2010-06-02 EP disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 PKM 2863/4885HTT 2073/4885HDAC1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.